1. The systemic treatment of recurrent ovarian cancer revisited
2. Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement
3. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer
4. Rucaparib versus standard‐of‐care chemotherapy in patients with relapsed ovarian cancer and a deleterious
BRCA1
or
BRCA2
mutation (ARIEL4);Kristeleit R.;Lancet Oncol,2022
5. Treatment perspectives for ovarian cancer in Europe and the United States: Initial therapy and platinum‐sensitive recurrence after PARP inhibitors or bevacizumab therapy;Laine A.;Curr Oncol Rep,2021